A phase 1a clinical trial of NRP-1 antibody MNRP1685A (Vesencumab®), targeting the against VEGF-binding site of NRP-1, was well-tolerated in cancer patients [62], but neuropathy was noted. Here, VEGFA is linked to neuropathy.